vidence that has accumulated over the years supports the use of oral misoprostol as a safe and inexpensive drug for labor induction. In 2012, the International Federation of Gynecology and Obstetrics (FIGO) recommended an oral dose of 25-mg misoprostol solution every 2 hours to induce labor, citing the 2011 World Health Organization (WHO) recommendations for labor induction. 1 The WHO strongly recommended this regimen by rating the quality of evidence as moderate 2 and including data from the 2006 Cochrane Review by Alfirevic and Weeks. 3 The more frequent dosing may address the short half-life of misoprostol, which is reported to reach a C max of 300e800 pg/mL in approximately 14e30 minutes, with a terminal half-life of 20e40 minutes. 4, 5 A 2014 Cochrane Review of oral misoprostol for labor induction included an additional 19 studies. 6 The authors confirmed the previous conclusion, stating that, if using oral misoprostol, then "the evidence suggests that the dose should be 20 to 25 mg" given every 2 hours. They added that "the evidence supports the use of oral regimens over vaginal regimens." The study by Cheng et al, 7 which compared hourly titrated-dose oral misoprostol with vaginal misoprostol, inspired us to explore a stepwise titration.
In our previous randomized clinical trial (RCT), we observed a 70% rate of vaginal delivery within 24 hours with the stepwise hourly titrated oral misoprostol solution regimen, which was greater than the 55% rate in women who were given the standard treatment of a dinoprostone vaginal insert (P¼.05). 8 However, this vaginal delivery rate with titrated oral misoprostol solution was significantly lower than the 94% that was achieved by Cheng et al. 7 Conversely, a simpler regimen, such as the FIGO-recommended static-dose misoprostol solution every 2 hours, 5 would enable a more widespread use of this drug. Therefore, the objective of this study was to compare the efficacy and safety of hourly titrated-dose oral misoprostol solution, as described by Cheng et al, 7 with the FIGO-recommended static-dose oral misoprostol solution every 2 hours for labor induction.
Materials and Methods
This open-label randomized trial was approved by the King Abdulaziz University Hospital (KAUH) institutional review board (KAUH study number 944-12). We enrolled all women who were admitted to KAUH (Jeddah, Saudi Arabia) for whom induction of labor was indicated by their attending obstetrician, who met the eligibility criteria, and who provided written informed consent. Inclusion criteria were (1) singleton live pregnancy, (2) !34 weeks gestation, (3) Bishop score 6, (4) intact membranes, (5) cephalic presentation, and (6) reassuring fetal heart rate. Exclusion criteria were (1) hypersensitivity to misoprostol, Original Research ajog.org (2) previous cesarean delivery or other uterine surgery, (3) severe pregnancyinduced hypertension (abnormal liver function test results, urine protein>1 g/d, blood pressure 160/100 mm Hg), (4) total pregnancies !4, (5) multiple gestations, (6) uterine contractions, and (7) significant maternal cardiac, renal, or liver disease. Women were assigned randomly (1:1) into the treatment groups (hourly titrated-dose or static dose every 2 hours) with the use of computer-generated numbers. Allocation concealment was carried out by the use of opaque envelopes that were distributed by the obstetrics nurse. Labor management at KAUH is standardized and includes electronic fetal monitoring that is performed 1 hour before and 1 hour after the start of induction and is continued after the beginning of uterine contractions until delivery. Intramuscular or intravenous analgesia is given for pain relief during labor. Delivery is carried out by in-house staff, usually residents and senior residents under the supervision of the oncall consultant.
Oral misoprostol solution was administered as a 1-mg/mL solution prepared from a 200-mg misoprostol tablet (Cytotec; Searle Pharmaceuticals, Leicester, United Kingdom) dissolved in 200 mL water, as previously described. 9 Cutting the tablets is difficult and imprecise; however, preparing a misoprostol solution allows precise dosing, and the misoprostol remains active in the solution for 24 hours. 6 The oral misoprostol solution was prepared fresh for each woman, and the unused solution was discarded. In the hourly titrated-dose group, the regimen described by Cheng et al 7 was used in the following manner: The starting dose was 20-mg (20 mL) oral misoprostol that was administered hourly for 4 doses; in the absence of regular uterine activity, the dose was increased to 40 mg (40 mL) hourly for 4 doses, and then to 60 mg (60 mL) for 16 doses. In the static-dose every 2 hours group, the recommended FIGO regimen was used in the following manner 5 : Oral misoprostol solution 25 mg (25 mL) was administered every 2 hours for a maximum of 12 doses or until the onset of regular uterine activity. In both groups, no further misoprostol was given once regular uterine activity was observed. If contractions subsequently became inadequate, oxytocin was provided !2 hours after the last misoprostol dose. Regular uterine activity was defined as regular uterine contractions every 3e5 minutes and lasting !60 seconds. The primary outcome was successful labor induction, defined as vaginal delivery within 24 hours after treatment initiation. Secondary outcomes were rate of cesarean delivery and need for oxytocin augmentation. Safety outcomes included incidence of maternal morbidity and adverse neonatal outcomes. Uterine tachysystole was defined as >5 contractions in a 10-minute period without fetal heart rate changes. Uterine hyperstimulation was defined as hypertonic uterine contractions or uterine tachysystole that was associated with fetal heart rate abnormalities. To minimize bias, abnormal fetal heart rate tracings, uterine contractile abnormalities, and other intrapartum events were determined and managed by the in-house staff and not post-hoc by the researchers.
The use of a projected 95% rate of vaginal delivery within 24 hours for the hourly titrated-dose misoprostol regimen, as described by Cheng et al, 7 and 80% rate for the recommended static-dose misoprostol regimen every 2 hours 10 would require 73 women per group (alpha¼.05 and 80% power). Our 70% rate of vaginal delivery within 24 hours for the stepwise hourly titrateddose misoprostol solution regimen from our previous RCT 8 was not used because the maximum cumulative dose in our study was 460 mg compared with 1120 mg in the study by Cheng et al, 7 which might have contributed to our lesser rate of vaginal deliveries within 24 hours.
Analysis was performed on an intentto-treat basis. The data were analyzed with the use of the Statistical Package for the Social Sciences (version 22.0; SPSS Inc, Chicago, IL). Dichotomous variables were compared between groups with c
Results
Of the 186 women who data were assessed for eligibility between December 2013 and July 2015, 146 women were assigned randomly to treatment (hourly titrated dose, 73 women; static-dose every 2 hours, 73; Figure) . Demographic and clinical factors were similar between groups, except for age (Table 1) . Patient age (meanAEstandard deviation) was 27.2AE5.3 years (range, 17e42 years) in the hourly titrated-dose group and 29.3AE5.1 years (range, 19e45 years) in the static-dose every 2 hours group (P¼.01). Postterm pregnancy was the primary indication for labor induction for 90 women (61.6%). Four women with premature rupture of the membranes at term were included in the study (titrated-dose group, 1 woman; static-dose group, 3 women). These 4 women with enrollment violations were included in the intent-to-treat analysis. Women in the hourly titrated-dose group received a median of 9 doses (range, 3e21); the median dose was 300 mg (range, 60e1020 mg). Women in the static-dose every 2 hours group received a median of 6 doses (range, 1e11); the median dose was 150 mg (range, 25e275 mg). The indication of induction of labor in the 17 women who delivered by cesarean section in the hourly titrated-dose group was postterm pregnancy in 9 women, pregnancy-induced hypertension in 2 women, intrauterine growth restriction in 1 woman, oligohydramnios in 1 woman, diabetes mellitus in 1 woman, and other indications in 3 women. The indication of induction of labor in the 6 women who delivered by cesarean section in the static dose every 2 hours group was postterm pregnancy in 3 women; intrauterine growth restriction in 1 woman, oligohydramnios in 1 woman, and other indication in 1 woman. Similarly, cesarean deliveries were performed within 24 hours after treatment in 9 women (53%) in the hourly titrated-dose group but in only 2 women (33.3%) in the static dose every 2 hours group (relative risk, 4.5; 95% confidence interval, 1.00e20.11; P¼.056). Proportions that achieved vaginal delivery within 24 hours did not differ significantly between treatment groups for women who were nulliparous (P¼1.00), who had postterm pregnancies (P¼.66), or who had a Bishop score 3 (P¼.84).
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The use of oxytocin was similar between the hourly titrated-dose group (n¼54; 73.9%) and the static dose every 2 hours group (n¼52; 71.2%; P¼.85). In addition, the proportions of women who were induced successfully after receiving oxytocin were similar between groups (P¼.83). Frequencies of maternal adverse events were similar between groups, except for pyrexia (Table 3) . No perinatal deaths occurred in the study population; however, more infants in the titrated-dose group had meconiumstained fluid (n¼23; 31.5%) compared with the static-dose group (n¼12; 16.4%; P¼.05; Table 4 ).
Comment
Misoprostol was approved by the US Food and Drug Administration for reducing the risk of nonsteroidal antiinflammatory drug-induced gastric ulcers but is used extensively off-label for labor induction, a common obstetric intervention. In 2002, the US Food and Drug Administration approved a new label for misoprostol that included the use of vaginal misoprostol for cervical ripening and labor induction without indicating efficacy, safety, doses, or dose intervals. 11 The American College of Obstetricians and Gynecologists reported that misoprostol is safe and effective for cervical ripening and labor induction and recommended a dose of 25 mg. 11 In addition, the WHO included misoprostol for labor induction in their Model List of Essential Drugs to emphasize its importance.
12 Although misoprostol is not approved for labor induction, its low cost, stability at room temperature, multiple administration routes, and greater acceptability with oral administration among pregnant women contributed to its widespread off-label use in Europe and most other countries. 13 The endorsement of misoprostol by professional organizations, which include FIGO, 1 WHO, 2 American College of Obstetricians and Gynecologists, 11 and Society of Obstetricians and Gynecologists of Canada, 14 is not shared by the National Institute for Health and Care Excellence, 15 which published a guidance document in 2008 that stated that "vaginal prostaglandin E 2 (PGE 2 ) is the preferred method of induction of labor, unless there are specific clinical reasons for not using it." However, neither the type of prostaglandin E 2 (gel, tablet, or sustained release pessary) nor the dose is specified. 16 The French College of Gynecologists and Obstetricians recommends a vaginal dose of 25-mg misoprostol every 3e6 hours but notes that "more powerful studies remain necessary for 18 The pivotal EXPEDITE trial, which provided data for regulatory submissions, reported vaginal delivery within 24 hours in 54.6% of women who were treated with the 200-mg misoprostol insert, but in only 34.0% of dinoprostone-treated women. A similar rate of cesarean deliveries between groups of slightly >25%, was reported, but tachysystole occurred significantly more often with misoprostol (13.3%) than with dinoprostone (4.0%; P<.05).
19
Numerous RCTs have evaluated labor induction methods. The latest Cochrane Review, which was based on 76 trials (14,412 women), recommends administering oral misoprostol solution as 20e25 mg every 2 hours. 6 The evidence supports the use of oral misoprostol regimens over vaginal misoprostol regimens as another Cochrane Review concluded that "the vaginal route should not be researched further." 20 However, study design and quality varied considerably among the included studies. The authors admitted that "methodologically sound clinical trials continue to be a priority, both in developing and industrialized countries" and that "a randomized examination comparing different regimens would be helpful to determine whether the laborintensive one-to two-hourly administration is necessary."
In our study, the 64.4% rate of vaginal delivery within 24 hours in the hourly titrated-dose misoprostol group was considerably lower than the rate reported by Cheng et al 7 In our study, the rates of cesarean delivery, side-effects, and complications were higher in the titrated-dose group than in the static-dose group. Although Cheng et al 7 reported no cases of hyperstimulation in the 101 women who received the titrated-dose misoprostol, in the current study we observed 1 case of uterine hyperstimulation in the titrated-dose group. In a dose-finding study of oral misoprostol for labor augmentation, no uterine hyperstimulation occurred with a dose of 50 mg every 2 hours. 21 Our neonatal intensive care unit admission rates in both treatment groups were within the reported ranges of previous studies that had evaluated oral misoprostol (0e12%).
22- 24 The results of our RCT indicate that the regimen of static-dose misoprostol solution every 2 hours has similar efficacy as the hourly titrateddose regimen but with fewer sideeffects and complications. In addition, the static-dose every 2 hours regimen is simpler and would allow more widespread use of oral misoprostol for labor induction.
Our findings should be interpreted with the following limitations in mind. Our RCT was not double-blinded to treatment. The sample size calculation was made with the primary endpoint (vaginal delivery within 24 hours) recommended by the WHO, 2 the 2014 Cochrane review, 6 and the National Institute for Health and Care Excellence. 15 To compare other measures of efficacy and safety would have required considerably more study participants; however, acquiring more subgroup data in a clinical trial setting may improve guidance on the use of oral misoprostol for specific populations for whom this off-label use is being introduced. n 
